Literature DB >> 28171865

How Can We Explain Very Low Odds Ratios in GWAS? I. Polygenic Models.

Susan E Hodge1, David A Greenberg.   

Abstract

Genome-wide association studies of common diseases often identify a number of disease-related SNPs that reach highly significant p values but at the same time show very low disease odds ratios (ORs), most <1.5 and many <1.2. Despite their statistical significance, associations involving very low ORs explain little about the genetic contribution to the disease and nothing about disease inheritance. A commonly accepted explanation for very low ORs involves a model of polygenic inheritance, i.e., where the disease being studied is caused by a large number of interacting genes, each gene contributing only a small increment to disease risk. Here we demonstrate the perhaps counterintuitive result that, within a reasonable range of disease population prevalences (≤10%), a pure polygenic model is incompatible with very low ORs, unless very large numbers (hundreds or even thousands) of polygenic loci are involved.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Keywords:  Case-control association analysis; Complex disorder; GWAS; Genetic heterogeneity; Genome-wide scan; Linkage disequilibrium; Odds ratios; Polygenic inheritance; Statistical genetics

Mesh:

Year:  2017        PMID: 28171865     DOI: 10.1159/000454804

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  10 in total

1.  Multi-Omic Approaches to Identify Genetic Factors in Metabolic Syndrome.

Authors:  Karen C Clark; Anne E Kwitek
Journal:  Compr Physiol       Date:  2021-12-29       Impact factor: 8.915

2.  Decomposing Pearson's χ2 test: A linear regression and its departure from linearity.

Authors:  Zhengyang Zhou; Hung-Chih Ku; Guan Xing; Chao Xing
Journal:  Ann Hum Genet       Date:  2018-05-31       Impact factor: 2.180

3.  Genome-wide association study identifies a locus associated with rotator cuff injury.

Authors:  Thomas R Roos; Andrew K Roos; Andrew L Avins; Marwa A Ahmed; John P Kleimeyer; Michael Fredericson; John P A Ioannidis; Jason L Dragoo; Stuart K Kim
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

4.  An efficient Bayesian meta-analysis approach for studying cross-phenotype genetic associations.

Authors:  Arunabha Majumdar; Tanushree Haldar; Sourabh Bhattacharya; John S Witte
Journal:  PLoS Genet       Date:  2018-02-12       Impact factor: 5.917

5.  Benchmarking bacterial genome-wide association study methods using simulated genomes and phenotypes.

Authors:  Morteza M Saber; B Jesse Shapiro
Journal:  Microb Genom       Date:  2020-03

6.  Using Genetic Risk Score Approaches to Infer Whether an Environmental Factor Attenuates or Exacerbates the Adverse Influence of a Candidate Gene.

Authors:  Wan-Yu Lin; Yu-Shun Lin; Chang-Chuan Chan; Yu-Li Liu; Shih-Jen Tsai; Po-Hsiu Kuo
Journal:  Front Genet       Date:  2020-05-08       Impact factor: 4.599

7.  Direct-to-consumer genetic testing.

Authors:  Jong-Won Kim
Journal:  Genomics Inform       Date:  2019-09-27

8.  CalPen (Calculator of Penetrance), a web-based tool to estimate penetrance in complex genetic disorders.

Authors:  Aditya Addepalli; Sakhare Kalyani; Minali Singh; Debashree Bandyopadhyay; K Naga Mohan
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

9.  Strength of immune selection in tumors varies with sex and age.

Authors:  Andrea Castro; Rachel Marty Pyke; Xinlian Zhang; Wesley Kurt Thompson; Chi-Ping Day; Ludmil B Alexandrov; Maurizio Zanetti; Hannah Carter
Journal:  Nat Commun       Date:  2020-08-17       Impact factor: 14.919

Review 10.  Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies.

Authors:  Danilo Cozzoli; Alessia Daponte; Salvatore De Fazio; Vincenza Ariano; Maria Rita Quaranta; Vincenzo Leone; Angelo Ostuni; Margherita Casanova; Claudia Rita Catacchio; Mario Ventura; Francesco Montinaro
Journal:  Biomedicines       Date:  2021-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.